GPR161

Chr 1ADARSomatic

G protein-coupled receptor 161

Also known as: RE2

The protein encoded by this gene is an orphan G protein-coupled receptor whose ligand is unknown. This gene is overexpressed in triple-negative breast cancer, and disruption of this gene slows the proliferation of basal breast cancer cells. Therefore, this gene is a potential drug target for triple-negative breast cancer. [provided by RefSeq, Mar 2017]

GeneReviewsOMIMResearchGenerating clinical summary…
MultiplemechanismAD/AR/SomaticLOEUF 0.798 OMIM phenotypes
Clinical SummaryGPR161
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
2 unique Pathogenic / Likely Pathogenic· 118 VUS of 185 total submissions
📖
GeneReview available — GPR161
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.79LOEUF
pLI 0.000
Z-score 2.28
OE 0.45 (0.270.79)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
1.51Z-score
OE missense 0.77 (0.690.85)
254 obs / 331.6 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.45 (0.270.79)
00.351.4
Missense OE?0.77 (0.690.85)
00.61.4
Synonymous OE?1.17
01.21.6
LoF obs/exp: 9 / 20.0Missense obs/exp: 254 / 331.6Syn Z: -1.54

This gene — mechanism propensity

DN
0.75top 25%
GOF
0.80top 10%
LOF
0.3357th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). The Badonyi & Marsh model scores gain-of-function highest among its predictions, but genomic evidence (constraint, ClinVar variant spectrum, and literature) most strongly supports dominant-negative. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median · 1 literature citation
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

DNDominant negative GPR161 rare variants are risk factors of human spina bifida.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

References

  1. 1.PMID 30256984

ClinVar Variant Classifications

185 submitted variants in ClinVar

Classification Summary

Pathogenic1
Likely Pathogenic1
VUS118
Likely Benign28
Benign19
Conflicting2
1
Pathogenic
1
Likely Pathogenic
118
VUS
28
Likely Benign
19
Benign
2
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
1
0
0
0
1
Likely Pathogenic
1
0
0
0
1
VUS
7
109
2
0
118
Likely Benign
0
3
4
21
28
Benign
1
2
2
14
19
Conflicting
2
Total10114835169

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

19 pathogenic / likely-pathogenic (of 22) ClinVar copy-number / structural variants overlap GPR161 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

GPR161 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →